EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53

Lingli Gong iD, Daxing Xu, Kaixiang Ni, Jie Li, Wei Mao, Bo Zhang, Zhening Pu, Xiangming Fang, Ying Yin, Li Ji, Jingjing Wang, Yaling Hu und 4 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202402258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Lingli Gong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, …. Hauptthemen laut MEDLINE: Glioblastoma, Tumor Suppressor Protein p53, Smad1 Protein, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Jiangsu Science and Technology Plan Special Funds (Key Research and Social Development), Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acetylation is critically required for p53 activation, though it remains poorly understood how p53 acetylation is regulated in glioblastoma (GBM). This study reveals that p53 acetylation is a favorable prognostic marker for GBM, regardless of p53 status, and that Smad1, a key negative regulator of p53 acetylation, is involved in this process. Smad1 forms a complex with p53 and p300, inhibiting p300's interaction with p53 and leading to reduced p53 acetylation and increased Smad1 acetylation in GBM. This results in enhanced tumor growth and resistance to chemotherapy, particularly in tumors with missense mutant p53. Acetylation of K373 is found to be essential for Smad1's oncogenic function but does not confer chemoresistance in the absence of p53. Through molecular docking, it is discovered that Smad1 and p53 both interact with the acetyltransferase domain of p300, but at different amino acid sites. Disturbing the interface of Smad1 through amino acid mutations abolishes the Smad1‐p300 complex and promotes p53 acetylation. Therefore, a small molecule is identified through virtual screening that specifically disrupts the Smad1‐p300 interaction, offering a promising strategy for inhibiting GBM and increasing chemosensitivity by inhibiting Smad1 acetylation and restoring p53 acetylation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTumor Suppressor Protein p53Smad1 ProteinDrug Resistance, NeoplasmE1A-Associated p300 ProteinBrain NeoplasmsHumansAcetylationMiceCell Line, TumorAnimalsCarcinogenesis

Stichwörter der Autor:innen

Smad1glioblastomap300p53

Substanzen

Tumor Suppressor Protein p53Smad1 ProteinEP300 protein, humanE1A-Associated p300 ProteinSMAD1 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, 214023, China.
  • Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, 214023, China.
  • Department of Neurosurgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, China.
  • Center of Clinical Research, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, China.
  • Department of Radiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, China.

ORCID-Profile: Lingli Gong, Jian Zou

Förderung

  • Natural Science Foundation of China
  • Jiangsu Science and Technology Plan Special Funds (Key Research and Social Development)
  • Natural Science Foundation of Jiangsu Province
  • General Program of Jiangsu Commission of Health
  • Wuxi Medical Innovation Team
  • Reserve Talents of Double Hundred Talent Plan
  • Top Talent Support Program for young and middle-aged people of Wuxi Health Committee
  • General Program of Wuxi Medical Center, Nanjing Medical University

Zitieren

APA

Gong, L., Xu, D., Ni, K., Li, J., Mao, W., Zhang, B., Pu, Z., Fang, X., Yin, Y., Ji, L., Wang, J., Hu, Y., Meng, J., Zhang, R., Jiao, J., & Zou, J. (2025). Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53. Advanced Science. https://doi.org/10.1002/advs.202402258

Vancouver

Gong L, Xu D, Ni K, Li J, Mao W, Zhang B, et al. Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53. Advanced Science. 2025. doi:10.1002/advs.202402258

BibTeX
@article{Gong2025,
  author = {Gong, Lingli and Xu, Daxing and Ni, Kaixiang and Li, Jie and Mao, Wei and Zhang, Bo and Pu, Zhening and Fang, Xiangming and Yin, Ying and Ji, Li and Wang, Jingjing and Hu, Yaling and Meng, Jiao and Zhang, Rui and Jiao, Jiantong and Zou, Jian},
  title = {Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202402258}
}
Kostenlos starten →